Aldn-084 Info

Key milestones to follow:

Search clinical trial registries and medical journals for the latest updates. ALDN-084

If proven effective and safe, ALDN-084 could offer: Key milestones to follow:

It would most likely be investigated first in adults with major depressive disorder, especially those with inadequate response to existing therapies. Search clinical trial registries and medical journals for

| Cellular read‑out | Effect of ALDN‑084 (in vitro) | |-------------------|------------------------------| | LPS‑stimulated macrophages (TNF‑α, IL‑1β) | ↓ > 80 % (IC₅₀ ≈ 10 nM) | | IFN‑γ‑primed astrocytes (CXCL10) | ↓ ≈ 70 % (IC₅₀ ≈ 25 nM) | | Oxidative stress (H₂O₂‑challenge) (ROS) | ↓ ≈ 55 % (EC₅₀ ≈ 80 nM) | | Phagocytic clearance of Aβ | ↑ ≈ 30 % (dose‑dependent, 100 nM) |